Pharmacologic disruption of NSUN2-ALYREF-MALAT1 signaling restores sorafenib sensitivity, positioning this pathway as an actionable target for overcoming TKI-tolerant tumor cells 62. The gene discussed is NSUN2; the disease is neoplasm.